| Bioactivity | OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research[1]. |
| Invitro | OK2 (0-100 μM；24 小时) 抑制 HK-2 细胞 EGFR 活化、 STAT3 磷酸化和 ECM 蛋白合成[1]。 Western Blot Analysis[1] Cell Line: |
| In Vivo | OK2 (50 μg/kg，腹腔注射，持续 14 天) 在单侧输尿管梗阻 (UUO) 小鼠模型中阻断 CCN2 诱导的 EGFR/STAT3 激活并阻止肾纤维化[1]。OK2 (皮下注射，1 mg/kg) 显示在雄性 Sprague Dawley 大鼠体内 T1/2 为 0.9 小时，C max 为 1057.8 ng/mL[1]。 Animal Model: |
| Name | OK2 |
| Sequence | cyclo-(Thr-Lys-His-Arg-Pro-Trp-Thr) |
| Shortening | cyclo-(TKHRPWT) |
| Formula | C42H62N14O9 |
| Molar Mass | 907.03 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dong J, et.al. Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment. J Med Chem. 2023 Jun 22;66(12):8251-8266. |